When was ImmuneID founded?

ImmuneID was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is ImmuneID located?

ImmuneID is headquartered in United States.

How many employees does ImmuneID have?

As of Mar 01, 2026, the latest employee count at ImmuneID is 10 - 49.

Is ImmuneID a funded company?

ImmuneID is a funded company, having raised a total of $70M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 17, 2021.

When was the latest funding round of ImmuneID?

ImmuneID's latest funding was a $***** Series A round on Jun 23, 2021, with participation from 9 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $3.31B in funding in 2026 to date.

Where does ImmuneID rank among its competitors?

ImmuneID ranks 1774th amongst 3691 active competitors, of which 1236 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of ImmuneID?

ImmuneID's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

ImmuneID - 2026 Company Profile, Funding & Competitors

ImmuneID is a deadpooled company based in United States, founded in 2020. It operates as a Developer of therapeutic solutions for multiple diseases. ImmuneID has raised $70M in funding from Alta Partners and Longwood Fund. The company has 3691 active competitors, including 1236 funded and 849 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutic solutions for multiple diseases. The company is engaged in the development of precision medicines that can interact with antibodies for treating autoimmune disorders, allergies, cancer, infectious diseases, and more.

Key Metrics

Founded Year

2020

Location

United States

Stage

Deadpooled

Total Funding

$70M in 2 rounds

Latest Funding Round

Series A, Jun 23, 2021, $*****

Investors

Alta Partners & 10 more

Ranked

1774^th among 3691 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Jazz Pharmaceuticals & 3515 more

View ImmuneID's full profile

ImmuneID has raised a total funding of $70M over 2 rounds. Its first funding round was on Feb 17, 2021. Its latest funding round was a Series A round on Jun 23, 2021 for $*****. 9 investors participated in its latest round. ImmuneID has 11 institutional investors.

Here is the list of recent funding rounds of ImmuneID:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 23, 2021	1207624	Series A	7328230	5771826	6655327	4649039
Feb 17, 2021	4407525	Series A	5955539	4641710	Longwood Fund	Arch Venture Partners & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of ImmuneID's funding rounds and investors

ImmuneID's employee count trend

ImmuneID has 10 - 49 employees as of Mar 26. Here is ImmuneID's employee count trend over the years:

Uncover ImmuneID's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ImmuneID include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ImmuneID, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1774th	ImmuneID 2020, United States, Deadpooled	Developer of therapeutic solutions for multiple diseases	$70M	Xfund, Tekla Capital Management & 9 others	32/100